2-amino-N-(3,4-dimethoxy-phenyl)-2-(2-methoxy-phenyl)-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-acetamide | 1111730-42-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-N-(3,4-dimethoxy-phenyl)-2-(2-methoxy-phenyl)-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-acetamide
• 英文别名: 2-amino-N-(3,4-dimethoxyphenyl)-2-(2-methoxyphenyl)-N-[2-[4-(trifluoromethyl)phenyl]ethyl]acetamide
• CAS: 1111730-42-7
• 化学式: C₂₆H₂₇F₃N₂O₄
• 分子量: 488.507
• InChiKey: ZBUZCCUVTLRJOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  [{(3,4-Dimethoxy-phenyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-carbamoyl}-(2methoxyphenyl)-methyl]-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以30%的产率得到2-amino-N-(3,4-dimethoxy-phenyl)-2-(2-methoxy-phenyl)-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-acetamide
  参考文献：
  名称：

  MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及以下式的化合物 其中 Ar，R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，n，o和p如本文所定义 或其药用合适的酸盐、光学纯对映体、拉氏体或二对映异构体混合物。式I的化合物可用于治疗睡眠障碍，如睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合征、昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。

  公开号：

  US20090036422A1

文献信息

• Methods and pharmaceutical compositions for the treatment of cancer
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10894042B2

  公开（公告）日：2021-01-19

  The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.

  本发明涉及治疗癌症的方法和药物组合物。更具体地说，本发明涉及一种治疗有需要的受试者癌症的方法，该方法包括向受试者施用治疗有效量的至少一种 OX1R 拮抗剂。
• USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
  申请人：Inserm (Institut National De La Sante et de la Recherche Medicale)

  公开号：US20190083508A1

  公开（公告）日：2019-03-21

  The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases.
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCJAE MÉDICALE

  公开号：US20190151304A1

  公开（公告）日：2019-05-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.
• [EN] MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS MONOAMIDE EN TANT QU'ANTAGONISTES DE RÉCEPTEURS AUX ORÉXINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016087A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of formula (I), wherein Ar is aryl or heteroaryl; R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, SO2-lower alkyl or hydroxy; R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, SO2-lower alkyl, NO2 or hydroxy; R3 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, -(CH2)m-O-lower alkyl, lower alkoxy substituted by halogen, 3-hydroxy-oxetan-3-yl, cyano or SO2-lower alkyl; or if o is 2, R3 may form in 3 and 4 position together with the carbon atoms to which they are attached an addional ring with the groups -O-CH2-O-, -O-CF2-CF2-O-, -N=CH-S-, -O-CF2-O-, -(CH2)4-, -NH-C(O)-NH-, -O-(CH2)2- or _(CH2)2-O-; R4/R5 are independently from each other hydrogen, -(CR'2)mOH, lower alkyl, lower alkoxy, -NRR', or is -(CH2)0,1-heterocycloalkyl, optionally substituted by hydroxy, or R4 and R5 are together =O or =N-OH,; R/R' are independently from each other hydrogen, lower alkyl, C(O)H, -(CR'2)m-OH, -(CR'2)m-NR'2, -(CR'2)m-NR'-C(O)-lower alkyl, -(CR'2)m-O-lower alkyl, -(CR'2)m-O-lower alkenyl, -C(O)O-lower alkyl, -C(O)-CR'2-NH-C(O)O-lower alkyl, -C(O)-CR'2-NR'2, or is -(CH2)0,1-heterocycloalkyl or -(CH2)0,1-furan-2-yl; R' are independently from each other hydrogen, lower alkoxy, phenyl or lower alkyl; n is 1, 2, 3 or 4; o is 1, 2 or 3; p is 1, 2 or 3; m is 1, 2 or 3; or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula (I) may be used for example for the treatment of the sleep disorders, which are sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
• MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090036422A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of formula wherein Ar, R 1 , R 2 , R 3 , R 4 , R 5 , n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

  本发明涉及以下式的化合物 其中 Ar，R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，n，o和p如本文所定义 或其药用合适的酸盐、光学纯对映体、拉氏体或二对映异构体混合物。式I的化合物可用于治疗睡眠障碍，如睡眠呼吸暂停症、嗜睡症、失眠、睡眠障碍、时差综合征、昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。